| 000 | 01710 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515174406.0 | ||
| 264 | 0 | _c20101116 | |
| 008 | 201011s 0 0 eng d | ||
| 022 | _a1520-6017 | ||
| 024 | 7 |
_a10.1002/jps.21819 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSuzuki, Toyofumi | |
| 245 | 0 | 0 |
_aBlood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. _h[electronic resource] |
| 260 |
_bJournal of pharmaceutical sciences _cJan 2010 |
||
| 300 |
_a413-21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aATP Binding Cassette Transporter, Subfamily B |
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiological Transport |
| 650 | 0 | 4 |
_aBlood-Brain Barrier _xmetabolism |
| 650 | 0 | 4 |
_aBrain _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHeLa Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMicroinjections |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aNaloxone _xadministration & dosage |
| 650 | 0 | 4 |
_aNarcotic Antagonists _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 | _aTissue Distribution |
| 700 | 1 | _aMiyata, Mariko | |
| 700 | 1 | _aZaima, Chika | |
| 700 | 1 | _aFuruishi, Takayuki | |
| 700 | 1 | _aFukami, Toshiro | |
| 700 | 1 | _aKugawa, Fumihiko | |
| 700 | 1 | _aTomono, Kazuo | |
| 773 | 0 |
_tJournal of pharmaceutical sciences _gvol. 99 _gno. 1 _gp. 413-21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/jps.21819 _zAvailable from publisher's website |
| 999 |
_c18948896 _d18948896 |
||